Una Recomendación de No Hacer es una indicación de abandonar una práctica clínica de escaso valor. El escaso valor lo determina el hecho de que la práctica no reporte ningún beneficio conocido para los pacientes y/o les ponga en riesgo de sufrir daños y además pueda suponer un derroche de recursos, sanitarios y/o sociales.
Las Recomendaciones de NO Hacer incluidas en el Catálogo son las que cumplen todos estos criterios.
Para solicitar la inclusión en el Catálogo, es preciso cumplimentar el formulario.
Ver más información sobre la Iniciativa NO Hacer
Walter HJ, Bukstein OG, Abright AR, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. [Internet.] 2020;59:1107-1124. [Consultado el 29/01/2022]. Disponible en: https://www.jaacap.org/article/S0890-8567(20)30280-X/fulltext
Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005170. doi: 10.1002/14651858.CD005170.pub2.
Grupo de Trabajo de la Guía de Práctica Clínica sobre Trastorno Bipolar. Guía de Práctica Clínica sobre Trastorno Bipolar. Madrid: Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Servicios Sociales e Igualdad. Universidad de Alcalá. Asociación Española de Neuropsiquiatría. 2012. UAH / AEN Núm. 2012/1.
Graham RK, Tavella G, Parker GB. Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? J Affect Disord. 2018 Mar 1;228:216-221.
Anmella G, Pacchiarotti I, Cubała WJ, Dudek D, Maina G, Thomas P, Vieta E. Expert advice on the management of valproate in women with bipolar disorder at childbearing age. Eur Neuropsychopharmacol. 2019 Nov;29(11):1199-1212.
Akther SF, Molyneaux E, Stuart R, Johnson S, Simpson A, Oram S. Patients' experiences of assessment and detention under mental health legislation: systematic review and qualitative meta-synthesis. BJPsych Open. 2019 Apr 24;5(3):e37. doi: 10.1192/bjo.2019.19.
Cusack P, Cusack FP, McAndrew S, McKeown M, Duxbury J. An integrative review exploring the physical and psychological harm inherent in using restraint in mental health inpatient settings. Int J Ment Health Nurs. 2018 Jun;27(3):1162-1176. doi: 10.1111/inm.12432. Epub 2018 Jan 19. PMID: 29352514.
Garrido E, Lizano I, Arissó P, Villagran J, Mur de Víu C. El coste económico de los procedimientos de contención mecánica de origen psiquiátrico en España. Psiquiatría Biológica. 2015;22. https://doi.org/10.1016/j.psiq.2015.04.002.
KSCCM clinical practice guidelines for pain, agitation, delirium, immobility, and sleep disturbance in the intensive care unit. Acute Crit Care. 2022 Feb;37(1):1-25. doi: 10.4266/acc.2022.00094.
NICE. National Institute for Health and Care Excellence. 2019 Delirium: prevention, diagnosis and management Clinical guideline Published: 28 July 2010. Last updated: 14 March 2019 www.nice.org.uk/guidance/cg103
Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, Needham DM. Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review. Ann Intern Med. 2019 Oct 1;171(7):485-495. doi: 10.7326/M19-1860
Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic Medication for Prevention and Treatment of Delirium in Hospitalized Adults: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2016 Apr;64(4):705-14. doi: 10.1111/jgs.14076. Epub 2016 Mar 23. Erratum in: J Am Geriatr Soc. 2016 Oct;64(10 ):2171-2173.
Mössner R, Mikova O, Koutsilieri E, Saoud M, Ehlis Ach, Müller N, Fallgatter AJ, Riederer P. Consensus Paper of the WFSBP Task Force On Biological Markers: Biological Markers in Depression. The World Journal of Biological Psychiatry 2007;8(3):141-174.
Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults Management in primary, secondary and community care. Issued: January 2011.NICE Clinical Guideline 113. guidance.nice.org.uk/cg113.
Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults Management in primary, secondary and community care. Issued: January 2011.NICE Clinical Guideline 113. guidance.nice.org.uk/cg113.
. Freire RC, Machado S, Arias-Carrión O, Nardi AE. Current pharmacological interventions in panic disorder. CNS Neurol Disord Drug Targets 2014;13(6).1057-65.
. Wang HR, Woo YS, Bahk WM. The potencial role of atypical antipsychotics in the treatment of panic disorder. Hum Psychopharmacol 2014;29(5):405-13.
Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs (2003);17:825-837.
Jacobson SA, Pies RW, Katz IR[Eds] Clinical Manual of Geriatric Psychopharmacology. America Psychiatric Publihing Inc.Washington DC, 2007.
Ohyon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews 2002;6(2):97-111.
Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000;48:682-685.
Sivertsen B, Krokstad S,Overlandd S, Mykletun A. The epidemiology of insomnia: Associations with physical and mental health. The HUNT-2 Study. J Psychosom Research 2009;67:109-116.
Smith AJ, Tett SE. Improving the use of benzodiazepines- Is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Services Research 2010;10:321.
Vinkers DJ, Gussekloo J, Van der Mast RC et al. Benzodiazepine use and risk of mortality in individuals aged 85 years or older. JAMA 2003;290:2942-2943.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults. Treatment and management Clinical Guideline Number 178 (CG178). Feb 2014 [Last Update: March 2014].
Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 1995;52:173-88.
Akbarpour F, Rezaei O, Khodaie- Ardakani MR, Sheikhvatan M, Goodarzi H, Dolatshahi B. A double-blind placebo controlled trial of bupropion for smoking abstinence and cognition improvement in schizophrenia. Minerva Psichiatrica 2010;51:263-269.